The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.
 
Christian Diego Rolfo
Consulting or Advisory Role - Mylan
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Guardant Health; MSD; Novartis
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Biomark (Inst); OncoDNA
 
Filippo G. De Braud
Honoraria - Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Ignyta; Incyte; Nerviano Medical Sciences; Octimet; Pierre Fabre; Roche; Sanofi; Teofarma
Speakers' Bureau - Menarini
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; GreenPeptide; Ignyta; OncoMed; Rain Therapeutics; Roche/Genentech; Takeda
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing fees for biologic materials from Black Diamond (Inst); Licensing fees for biologic materials from Foundation Medicine (Inst); Licensing fees for biologic materials from Genentech (Inst); Licensing fees for patent from Rain Therapeutics; Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - Ignyta; Rain Therapeutics; Roche/Genentech
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; MORE Health; Pfizer; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Manish Patel
Consulting or Advisory Role - Nektar
 
Byoung Chul Cho
Stock and Other Ownership Interests - Bridgebio; Gencurix; Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Stephen V. Liu
Consulting or Advisory Role - Apollomics; ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Genentech; Guardant Health; HERON; Ignyta; Inivata; Janssen Oncology; Lilly; Loxo; Merck; MSD Oncology; Pfizer; PharmaMar; Regeneron; Roche; Taiho Pharmaceutical; Takeda; Tempus
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Esanex (Inst); Genentech/Roche (Inst); Ignyta (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Molecular Partners (Inst); OncoMed (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Lilly; MSD; TAKEDA
Consulting or Advisory Role - Alpha pharmaceutical; AstraZeneca; Boehringer Ingelheim; Lilly; MSD; TAKEDA
 
Chao-Hua Chiu
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Roche
 
Anna F. Farago
Honoraria - Clinical Care Options; Medscape; Peerview; Research to Practice
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; H3 Biomedicine; Loxo; Merck; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Loxo; Medscape; Merck; Peerview
 
Koichi Goto
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guardant Health; IQvia; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo
 
Jeeyun Lee
Consulting or Advisory Role - Oncologie; Seagen
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Boehringer Ingelheim; G1 Therapeutics; Genentech/Roche; Loxo; Novartis; Takeda
Research Funding - BeyondSpring Pharmaceuticals
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Brian P. Simmons
Employment - Roche
 
Bethany Pitcher
Employment - Roche
 
Xinhui Huang
Employment - Roche
 
George D. Demetri
Leadership - Blueprint Medicines; Merrimack; Translate BIO
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; Merrimack; Relay Therapeutics; Translate BIO
Consulting or Advisory Role - Acrivon Therapeutics; Adaptimmune; Arsenal Capital; Bayer; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; ICON Clinical Research; Ignyta; Janssen Oncology; Loxo; Medscape; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Polaris; Relay Therapeutics; Roche/Genentech; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); AbbVie (Inst); Adaptimmune (Inst); Bayer (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Janssen Oncology (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
Expert Testimony - Epizyme